Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Shares Issued (2023 - 2025)

CG Oncology (CGON) has disclosed Shares Issued for 3 consecutive years, with -$42.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 119.27% year-over-year to -$42.5 million, compared with a TTM value of $6.5 million through Dec 2025, down 97.11%, and an annual FY2025 reading of $6.5 million, down 97.11% over the prior year.
  • Shares Issued was -$42.5 million for Q4 2025 at CG Oncology, down from $48.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $406.4 million in Q1 2024 and bottomed at -$404.2 million in Q3 2024.
  • Average Shares Issued over 3 years is $21.1 million, with a median of $262000.0 recorded in 2023.
  • Peak annual rise in Shares Issued hit 597561.76% in 2024, while the deepest fall reached 25567.3% in 2024.
  • Year by year, Shares Issued stood at $262000.0 in 2023, then soared by 84180.53% to $220.8 million in 2024, then tumbled by 119.27% to -$42.5 million in 2025.
  • Business Quant data shows Shares Issued for CGON at -$42.5 million in Q4 2025, $48.3 million in Q3 2025, and $19000.0 in Q2 2025.